Stockholders' Equity - Additional Information (Details)

v3.25.1

Stockholders' Equity - Additional Information (Details)							1 Months Ended											12 Months Ended
	Jan. 01, 2025 shares	May 16, 2024 shares	May 13, 2024 $ / shares shares	Jan. 01, 2024	Oct. 04, 2023 USD ($)	Mar. 17, 2015 shares	Mar. 31, 2025 USD ($) $ / shares	Jan. 31, 2025 USD ($) $ / shares	Nov. 30, 2024 USD ($) $ / shares shares	Oct. 31, 2024 USD ($)	Jul. 31, 2024 USD ($) $ / shares shares	Jan. 31, 2024 USD ($) $ / shares shares	Oct. 31, 2023 USD ($) $ / shares shares	Jul. 31, 2023 USD ($) $ / shares shares	May 31, 2023 USD ($) $ / shares shares	Apr. 30, 2023 USD ($) $ / shares shares	Feb. 28, 2023 USD ($) $ / shares shares	Dec. 31, 2024 USD ($) Vote multiplier $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares	Mar. 09, 2025 $ / shares shares	Nov. 30, 2023 shares	Mar. 31, 2023 USD ($)	Dec. 31, 2022 $ / shares shares	Dec. 16, 2022 $ / shares shares	Nov. 30, 2020 USD ($)
Stockholders' Equity
Common stock, increase in the number of authorized shares (in shares)			95,000,000
Common stock, shares authorized			175,000,000															175,000,000	80,000,000
Common stock, par value (in dollars per share) | $ / shares			$ 0.0001															$ 0.0001	$ 0.0001
Common stock, shares outstanding																		53,640,422	27,042,035
Common stock, shares issued																		53,640,422	27,042,035
Shelf registration statement, maximum authorized securities | $																									$ 100,000,000
Number of warrants issued													110,000
Number of warrants issued and sold to purchase shares																			1,134,000		6,215,354
Total gross proceeds from Issuance of common stock | $																		$ 26,000,000	$ 33,621,000
Amount of commissions and other transaction costs | $																		2,408,000	3,289,000
Proceeds from Warrant | $																		$ 9,185,000	11,134,000
Warrant inducement expense | $					$ 1,200,000
Deemed dividends | $																			$ 7,500,000
Common stock shares issuable																		2,386,808	1,492,915
Payment of transactional costs for exercise of warrants | $																			$ 1,016,000
Gain Loss On Common Stock Warrant Liabilities | $																		$ (73,000)	$ 217,000
Pre-funded warrants
Stockholders' Equity
Class of warrants exercise price | $ / shares											$ 0.0001	$ 0.0001		$ 0.0001	$ 0.0001		$ 0.0001
February 2023 Common Stock Warrants
Stockholders' Equity
Warrant inducement expense | $																		1,100,000
Deemed dividends | $																		6,300,000
December 2022 Common Stock Warrants
Stockholders' Equity
Gain Loss On Common Stock Warrant Liabilities | $					$ (7,700,000)
Non-vested restricted stock
Stockholders' Equity
Total unrecognized compensation cost related to non-vested | $																		$ 4,800,000
Weighted average period (in years)																		1 year 8 months 12 days
Restricted Stock Units
Stockholders' Equity
Restricted stock outstanding non-vested																			615,884				85,000
Number of Shares, Vested																		2,798,246	42,500
Stock-based compensation expense | $																		$ 5,700,000
Restricted Stock
Stockholders' Equity
Restricted stock outstanding non-vested																		4,887,499	1,316,120				378,897
Number of Shares, Vested																		1,500,000
Number of Shares, Vested																		1,751,033	111,375
Stock-based compensation expense | $																		$ 4,400,000
2015 Incentive Plan
Stockholders' Equity
Number of shares available for issuance authorized			18,000,000
Shares are available for issuance																		8,010,406
Plans expires (in years)			10 years
Subsequent Event
Stockholders' Equity
Class of warrants exercise price | $ / shares							$ 1.66													$ 3.62
Number of shares issuable for each warrant																				5,853,659
Proceeds from Warrant | $							$ 36,000,000
February 2023 Registered Direct Offering
Stockholders' Equity
Number of shares issued and sold																	1,180,000
Purchase price per share | $ / shares																	$ 5.25
Number of warrants issued																	248,572
Class of warrants exercise price | $ / shares													$ 5
Total gross proceeds from Issuance of common stock | $																	$ 7,500,000
Net proceeds from offering | $																	6,700,000
Amount of commissions and other transaction costs | $																	$ 800,000
February 2023 Registered Direct Offering | Pre-funded warrants
Stockholders' Equity
Number of warrants issued																	248,572
Warrants offering price | $ / shares																	$ 5.2499
Class of warrants exercise price | $ / shares																	5.2499
February 2023 Registered Direct Offering | Series A Warrants
Stockholders' Equity
Class of warrants exercise price | $ / shares																	$ 5
Number of warrants issued and sold to purchase shares																	1,428,572
Expiration term of warrants (in years)																	5 years
February 2023 Registered Direct Offering | Series B Warrants
Stockholders' Equity
Class of warrants exercise price | $ / shares																	$ 5.00
Expiration term of warrants (in years)																	18 months
February 2023 Registered Direct Offering | Placement Agent Warrants
Stockholders' Equity
Class of warrants exercise price | $ / shares																	$ 6.5625
Number of warrants issued and sold to purchase shares																	85,714
February 2023 Registered Direct Offering | Maximum | Series A Warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares																	1,428,572
February 2023 Registered Direct Offering | Maximum | Series B Warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares																	1,428,572
April 2023 Direct Offering
Stockholders' Equity
Number of shares issued and sold																1,700,000
Purchase price per share | $ / shares																$ 3.6
Total gross proceeds from Issuance of common stock | $																$ 6,100,000
Net proceeds from offering | $																5,500,000
Amount of commissions and other transaction costs | $																$ 600,000
Shelf registration statement remaining authorized securities | $																						$ 150,000,000
April 2023 Direct Offering | Series A Warrants
Stockholders' Equity
Class of warrants exercise price | $ / shares																$ 3.35
Expiration term of warrants (in years)																5 years
April 2023 Direct Offering | Series B Warrants
Stockholders' Equity
Class of warrants exercise price | $ / shares																$ 3.35
Expiration term of warrants (in years)																18 months
April 2023 Direct Offering | Placement Agent Warrants
Stockholders' Equity
Class of warrants exercise price | $ / shares																$ 4.5
Number of warrants issued and sold to purchase shares																102,000
April 2023 Direct Offering | Maximum | Series A Warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares																1,700,000
April 2023 Direct Offering | Maximum | Series B Warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares																1,700,000
May 2023 Registered Direct Offering
Stockholders' Equity
Number of shares issued and sold															1,650,000
Purchase price per share | $ / shares															$ 3.071
Class of warrants exercise price | $ / shares															$ 3.0709
Shares held in abeyance																		1,437,000
Total gross proceeds from Issuance of common stock | $															$ 10,000,000
Net proceeds from offering | $															9,100,000
Amount of commissions and other transaction costs | $															$ 900,000
May 2023 Registered Direct Offering | Pre-funded warrants
Stockholders' Equity
Number of warrants issued															1,606,269
Class of warrants exercise price | $ / shares															$ 3.0709
May 2023 Registered Direct Offering | Series A Warrants
Stockholders' Equity
Class of warrants exercise price | $ / shares															$ 2.821
Expiration term of warrants (in years)															5 years
May 2023 Registered Direct Offering | Series B Warrants
Stockholders' Equity
Class of warrants exercise price | $ / shares									$ 2.821						$ 2.821
Shares held in abeyance																		1,437,000
Number of warrants issued and sold to purchase shares									3,256,269
Expiration term of warrants (in years)															18 months
Proceeds from issuance of warrants | $									$ 9,200,000
May 2023 Registered Direct Offering | Placement Agent Warrants
Stockholders' Equity
Class of warrants exercise price | $ / shares															$ 3.8388
Number of warrants issued and sold to purchase shares															195,376
May 2023 Registered Direct Offering | Maximum | Series A Warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares															3,256,269
May 2023 Registered Direct Offering | Maximum | Series B Warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares															3,256,269
July 2023 Registered Direct Offering
Stockholders' Equity
Number of shares issued and sold														2,427,186
Purchase price per share | $ / shares														$ 3.09
Total gross proceeds from Issuance of common stock | $														$ 10,000,000
Net proceeds from offering | $														9,100,000
Amount of commissions and other transaction costs | $														$ 900,000
July 2023 Registered Direct Offering | Pre-funded warrants
Stockholders' Equity
Number of warrants issued														809,062
Class of warrants exercise price | $ / shares														$ 3.0899
Number of warrants issued and sold to purchase shares														809,062
July 2023 Registered Direct Offering | Series A Warrants
Stockholders' Equity
Class of warrants exercise price | $ / shares														$ 2.84
Expiration term of warrants (in years)														5 years
July 2023 Registered Direct Offering | Series B Warrants
Stockholders' Equity
Class of warrants exercise price | $ / shares														$ 2.84
Expiration term of warrants (in years)														18 months
July 2023 Registered Direct Offering | Placement Agent Warrants
Stockholders' Equity
Class of warrants exercise price | $ / shares														$ 3.8625
Number of warrants issued and sold to purchase shares														194,175
July 2023 Registered Direct Offering | Subsequent Event | Series B Warrants
Stockholders' Equity
Class of warrants exercise price | $ / shares								$ 2.84
Proceeds from Warrant | $								$ 2,100,000
July 2023 Registered Direct Offering | Maximum | Series A Warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares														3,236,248
July 2023 Registered Direct Offering | Maximum | Series B Warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares														3,236,248
January 2024 Registered Direct Offering
Stockholders' Equity
Number of shares issued and sold												1,275,000
Purchase price per share | $ / shares												$ 1.805
Class of warrants exercise price | $ / shares												$ 1.8049
Total gross proceeds from Issuance of common stock | $												$ 14,000,000
Net proceeds from offering | $												12,600,000
Amount of commissions and other transaction costs | $												$ 1,400,000
January 2024 Registered Direct Offering | Pre-funded warrants
Stockholders' Equity
Number of warrants issued												6,481,233
Class of warrants exercise price | $ / shares												$ 1.8049
January 2024 Registered Direct Offering | Placement Agent Warrants
Stockholders' Equity
Class of warrants exercise price | $ / shares												$ 2.2563
Number of warrants issued and sold to purchase shares												465,374
January 2024 Registered Direct Offering | Common Stock Warrants
Stockholders' Equity
Class of warrants exercise price | $ / shares												$ 1.68
Expiration term of warrants (in years)												5 years
January 2024 Registered Direct Offering | Maximum | Common Stock Warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares												7,756,233
July 2024 Registered Direct Offering
Stockholders' Equity
Number of shares issued and sold											1,230,000
Purchase price per share | $ / shares											$ 2.05
Number of warrants issued											4,623,659
Class of warrants exercise price | $ / shares											$ 2.0499
Total gross proceeds from Issuance of common stock | $											$ 12,000,000
Net proceeds from offering | $											11,000,000
Amount of commissions and other transaction costs | $											$ 1,000,000
July 2024 Registered Direct Offering | Pre-funded warrants
Stockholders' Equity
Number of warrants issued											4,623,659
Class of warrants exercise price | $ / shares											$ 2.0499
July 2024 Registered Direct Offering | Placement Agent Warrants
Stockholders' Equity
Class of warrants exercise price | $ / shares											$ 2.5625
Number of warrants issued and sold to purchase shares											351,220
July 2024 Registered Direct Offering | Common Stock Warrants
Stockholders' Equity
Class of warrants exercise price | $ / shares											$ 2.05
Expiration term of warrants (in years)											5 years
July 2024 Registered Direct Offering | Maximum | Common Stock Warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares											5,853,659
October 2023 Registered Direct Offering
Stockholders' Equity
Class of warrants exercise price | $ / shares													$ 1.76				$ 5						$ 4.075
Shares held in abeyance																			1,134,000
Number of warrants issued and sold to purchase shares													6,325,354
Total gross proceeds from Issuance of common stock | $													$ 11,100,000
Net proceeds from offering | $										$ 10,000			10,000,000
Amount of commissions and other transaction costs | $													1,100,000
Proceeds from Warrant | $													11,100,000
Payment of transactional costs for exercise of warrants | $													$ 1,100,000
October 2023 Registered Direct Offering | Series A Warrants
Stockholders' Equity
Class of warrants exercise price | $ / shares													$ 1.51
Expiration term of warrants (in years)													5 years
October 2023 Registered Direct Offering | Series B Warrants
Stockholders' Equity
Class of warrants exercise price | $ / shares													$ 1.51
Expiration term of warrants (in years)													24 months
October 2023 Registered Direct Offering | Placement Agent Warrants
Stockholders' Equity
Class of warrants exercise price | $ / shares													$ 2.2
Number of warrants issued and sold to purchase shares													379,521
October 2023 Registered Direct Offering | February 2023 Common Stock Warrants
Stockholders' Equity
Class of warrants exercise price | $ / shares													$ 1.76
October 2023 Registered Direct Offering | Maximum | Series A Warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares													6,325,354
October 2023 Registered Direct Offering | Maximum | Series B Warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares													6,325,354
December 2022 direct offering
Stockholders' Equity
Class of warrants exercise price | $ / shares													$ 4.075
December 2022 direct offering | Series A Warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares													1,734,105
December 2022 direct offering | Series B Warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares													1,734,105
December 2022 direct offering | Placement Agent Warrants
Stockholders' Equity
Class of warrants exercise price | $ / shares																								$ 5.406
December 2022 direct offering | Common Stock Warrants
Stockholders' Equity
Class of warrants exercise price | $ / shares													$ 1.76
December 2022 direct offering | Maximum | Placement Agent Warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares																								104,046
Fortress Biotech, Inc
Stockholders' Equity
Number of shares issued and sold																		421,653	398,660
Percentage of annual equity fee		2.50%																2.50%
Issuance of common shares - Founders agreement | $																		$ 1,000,000	$ 1,000,000
Percentage of shares issued for offering and annual equity fee	2.50%
Common stock shares issuable		1,492,915
Fortress Biotech, Inc
Stockholders' Equity
Number of shares issued and sold	2,386,808
Shelf registration statement remaining authorized securities | $																		65,700,000
Related Party | Fortress Biotech, Inc
Stockholders' Equity
Number of shares issued and sold		1,492,915				2,386,808
Percentage of shares issued for offering and annual equity fee				2.50%		2.50%
Non-cash research and development expenses | $																		$ 7,600,000	$ 3,400,000
Common Stock
Stockholders' Equity
Number of votes per share | Vote																		1
Multiplier to calculate voting rights per class A common share | multiplier																		1.1
Number of non assessable shares issued upon conversion																		1
Common Stock | July 2023 Registered Direct Offering
Stockholders' Equity
Number of shares issued and sold														2,427,186
Purchase price per share | $ / shares														$ 3.09
Common Stock | January 2024 Registered Direct Offering
Stockholders' Equity
Number of shares issued and sold												1,275,000
Class of warrants exercise price | $ / shares												$ 1.68
Expiration term of warrants (in years)												5 years
Common Stock | January 2024 Registered Direct Offering | Maximum
Stockholders' Equity
Number of warrants issued and sold to purchase shares												7,756,233
Common Stock | July 2024 Registered Direct Offering
Stockholders' Equity
Number of shares issued and sold											1,230,000
Class of warrants exercise price | $ / shares											$ 2.05
Expiration term of warrants (in years)											5 years
Common Stock | July 2024 Registered Direct Offering | Maximum
Stockholders' Equity
Number of warrants issued and sold to purchase shares											5,853,659
Warrants
Stockholders' Equity
Expiration term of warrants (in years)																		3 years 1 month 2 days	3 years				3 years 3 months 3 days
Warrants, Exercised																		(14,361,161)	(9,773,501)
Warrants, Granted																		25,531,378	35,513,575
Common Class A
Stockholders' Equity
Common stock, shares authorized			700,000
Common stock, shares outstanding																		700,000	700,000
Common stock, shares issued																		700,000	700,000